Home  /  Resource Library  /  CLL-045: Long Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)

CLL-045: Long Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)

Long term results of a study examining ibrutinib for first line treatment of CLL. (Abstract only)